Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review

References

• Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008;255(S6):2–6. doi:10.1007/s00415-008-6001-2
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12):2899–2912. doi:10.1084/jem.20071030
   PubMed Web of Science ®Google Scholar
• Sospedra M, Martin R. IMMUNOLOGY OF MULTIPLE SCLEROSIS. Annu Rev Immunol. 2005;23(1):683–747. doi:10.1146/annurev.immunol.23.021704.115707
   PubMed Web of Science ®Google Scholar
• Zéphir H. Progress in understanding the pathophysiology of multiple sclerosis. Rev Neurol (Paris). 2018;174(6):358–363. doi:10.1016/j.neurol.2018.03.006
   Web of Science ®Google Scholar
• Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6(10):1167–1175. doi:10.1038/80516
   PubMed Web of Science ®Google Scholar
• Probert L, Eugster HP, Akassoglou K, et al. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain. 2000;123(Pt 10):2005–2019. doi:10.1093/brain/123.10.2005
   PubMed Web of Science ®Google Scholar
• Willenborg DO, Staykova M, Fordham S, O’Brien N, Linares D. The contribution of nitric oxide and interferon gamma to the regulation of the neuro-inflammation in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2007;191(1–2):16–25. doi:10.1016/j.jneuroim.2007.09.007
   PubMed Web of Science ®Google Scholar
• Flügel A, Berkowicz T, Ritter T, et al. Migratory Activity and Functional Changes of Green Fluorescent Effector Cells before and during Experimental Autoimmune Encephalomyelitis. Immunity. 2001;14(5):547–560. doi:10.1016/S1074-7613(01)00143-1
   Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286. doi:10.1212/WNL.0000000000000560
   PubMed Web of Science ®Google Scholar
• Sawcer S, Hellenthal G, Pirinen M. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–219. doi:10.1038/nature10251
   PubMed Web of Science ®Google Scholar
• Fugger L, Friese MA, Bell JI. From genes to function: the next challenge to understanding multiple sclerosis. Nat Rev Immunol. 2009;9(6):408–417. doi:10.1038/nri2554
   PubMed Web of Science ®Google Scholar
• Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014;10(4):225–238. doi:10.1038/nrneurol.2014.37
   PubMed Web of Science ®Google Scholar
• Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;18(12):905–922. doi:10.1038/s41573-019-0035-2
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Eng J Med. 2006;354(9):899–910. doi:10.1056/NEJMoa044397
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, et al. A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Eng J Med. 2003;348(1):15–23. doi:10.1056/NEJMoa020696
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. N Eng J Med. 2006;354(9):911–923. doi:10.1056/NEJMoa044396
   PubMed Web of Science ®Google Scholar
• Tysabri prescribing information. Available from: https://www.tysabrihcp.com/content/dam/commercial/tysabri/hcp/en_us/pdf/tysabri_prescribing_information.pdf. Accessed December 2, 2021.
   Google Scholar
• Lexicomp. Natalizumab: drug information. Available from: https://www.uptodate.com/contents/natalizumab-drug-information?search=natalizumab&source=panel_search_result&selectedTitle=1~36&usage_type=panel&kp_tab=drug_general&display_rank=1. Accessed June 3, 2021.
   Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. N Eng J Med. 2012;366(20):1870–1880. doi:10.1056/NEJMoa1107829
   PubMed Web of Science ®Google Scholar
• Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Natalizumab-associated WH. PML. Neurology. 2017;88(12):1197–1205. doi:10.1212/WNL.0000000000003739
   PubMed Web of Science ®Google Scholar
• Ho P-R, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurology. 2017;16(11):925–933. doi:10.1016/S1474-4422(17)30282-X
   PubMed Web of Science ®Google Scholar
• Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802–812. doi:10.1002/ana.24286
   PubMed Web of Science ®Google Scholar
• Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019. doi:10.1212/WNL.0000000000008243
   Web of Science ®Google Scholar
• Yamout BI, Sahraian MA, Ayoubi NE, et al. Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord. 2018;24:113–116. doi:10.1016/j.msard.2018.06.015
   PubMed Web of Science ®Google Scholar
• Clerico M, De Mercanti SF, Signori A, et al. Extending the Interval of Natalizumab Dosing: is Efficacy Preserved? Neurotherapeutics. 2020;17(1):200–207. doi:10.1007/s13311-019-00776-7
   PubMed Web of Science ®Google Scholar
• Gueguen A, Roux P, Deschamps R, et al. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(9):1038–1040. doi:10.1136/jnnp-2014-307591
   Web of Science ®Google Scholar
• Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261(6):1170–1177. doi:10.1007/s00415-014-7325-8
   PubMed Web of Science ®Google Scholar
• Vidal-Jordana A, Tintoré M, Tur C, et al. Significant clinical worsening after natalizumab withdrawal: predictive factors. Multiple Sclerosis J. 2015;21(6):780–785. doi:10.1177/1352458514549401
   Web of Science ®Google Scholar
• González-Suarez I, Rodríguez De Antonio L, Orviz A, et al. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav. 2017;7(4):e00671. doi:10.1002/brb3.671
   PubMed Web of Science ®Google Scholar
• Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BMJ, Polman CH. POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS. Neurology. 2008;70(Issue 13, Part 2):1150–1151. doi:10.1212/01.wnl.0000265393.03231.e5
   Web of Science ®Google Scholar
• Larochelle C, Metz I, Lécuyer M-A, et al. Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. Multiple Sclerosis J. 2017;23(1):72–81. doi:10.1177/1352458516641775
   Web of Science ®Google Scholar
• Fuentes-Rumí L, Hernández-Clares R, Carreón-Guarnizo E, et al. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules. Mult Scler Relat Disord. 2020;44:102311. doi:10.1016/j.msard.2020.102311
   Web of Science ®Google Scholar
• Langer-Gould AM. Pregnancy and Family Planning in Multiple Sclerosis. Continuum. 2019;25(3):773–792. doi:10.1212/CON.0000000000000745
   Google Scholar
• Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391–1403. doi:10.1212/01.wnl.0000277457.17420.b5
   PubMed Web of Science ®Google Scholar
• Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Multiple Sclerosis J. 2013;19(5):593–600. doi:10.1177/1352458512460604
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled Phase 3 trial. The Lancet. 2012;380(9856):1819–1828. doi:10.1016/S0140-6736(12)61769-3
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration CfDEaR. Lemtrada (alemtuzumab) BLA 103948/5139 approval letter. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/103948Orig1s5139ltr.pdf. Accessed June 3, 2021.
   Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839. doi:10.1016/S0140-6736(12)61768-1
   PubMed Web of Science ®Google Scholar
• Lexicomp. Alemtuzumab: drug Information. Available from: https://www.uptodate.com/contents/alemtuzumab-drug-information?search=alemtuzumab&source=panel_search_result&selectedTitle=1~137&usage_type=panel&kp_tab=drug_general&display_rank=1. Accessed June 3, 2021.
   Google Scholar
• Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86(2):208–215. doi:10.1136/jnnp-2014-307721
   PubMed Web of Science ®Google Scholar
• Holmøy T, Fevang B, Olsen DB, Spigset O, Bø L. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Res Notes. 2019;12(1):1. doi:10.1186/s13104-019-4507-6
   PubMed Web of Science ®Google Scholar
• Romba MC, Newsome SD, Mcarthur JC. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2019;34:100–102. doi:10.1016/j.msard.2019.06.022
   PubMed Web of Science ®Google Scholar
• Habek M, Ruška B, Pavičić T, Alduk AM, Gabelić T, Adamec I. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;35:5–6. doi:10.1016/j.msard.2019.06.032
   Web of Science ®Google Scholar
• Hartung H-P, Mares J, Barnett MH. Alemtuzumab: rare serious adverse events of a high-efficacy drug. Multiple Sclerosis J. 2020;26(6):737–740. doi:10.1177/1352458520913277
   Web of Science ®Google Scholar
• Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):298–304. doi:10.1136/jnnp-2011-300826
   PubMed Web of Science ®Google Scholar
• Meltzer E, Campbell S, Ehrenfeld B, et al. Mitigating alemtuzumab-associated autoimmunity in MS. Neurol Neuroimmunology Neuroinflammation. 2020;7(6):e868. doi:10.1212/NXI.0000000000000868
   Web of Science ®Google Scholar
• Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678–1685.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis. N Eng J Med. 2008;358(7):676–688. doi:10.1056/NEJMoa0706383
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PAJ, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395–400. doi:10.1002/ana.21363
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis. Neurology. 2016;87(20):2074–2081. doi:10.1212/WNL.0000000000003331
   PubMed Web of Science ®Google Scholar
• Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis. Multiple Sclerosis J. 2020;26(2):137–152. doi:10.1177/1352458519858604
   Web of Science ®Google Scholar
• Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis. Neurotherapeutics. 2017;14(4):835–841. doi:10.1007/s13311-017-0557-4
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460–471. doi:10.1002/ana.21867
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Eng J Med. 2017;376(3):221–234. doi:10.1056/NEJMoa1601277
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Eng J Med. 2017;376(3):209–220. doi:10.1056/NEJMoa1606468
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Eng J Med. 2020;383(6):546–557. doi:10.1056/NEJMoa1917246
   PubMed Web of Science ®Google Scholar
• Ocrevus Prescribing Information. Available from: https://www.gene.com/download/pdf/ocrevus_prescribing.pdf. Accessed June 3, 2021.
   Google Scholar
• Kesimpta Prescribing Information. Available from: https://www.novartis.us/sites/www.novartis.us/files/kesimpta.pdf. Accessed June 3, 2021.
   Google Scholar
• Reder AT, Centonze D, Naylor ML, et al. COVID-19 in Patients with Multiple Sclerosis: associations with Disease-Modifying Therapies. CNS Drugs. 2021;35(3):317–330. doi:10.1007/s40263-021-00804-1
   PubMed Web of Science ®Google Scholar
• Sormani MP, De Rossi N, Schiavetti I, et al. Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. SSRN Electronic J. 2020. doi:10.2139/ssrn.3631244
   Google Scholar
• Hughes R, Whitley L, Fitovski K, et al. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord. 2021;49:102725. doi:10.1016/j.msard.2020.102725
   PubMed Web of Science ®Google Scholar
• Vaccinations. National Multiple Sclerosis Society. Available from: https://www.nationalmssociety.org/Living-Well-With-MS/Diet-Exercise-Healthy-Behaviors/Vaccinations. Accessed June 3, 2021.
   Google Scholar
• Timing MS Medications with COVID-19 mRNA Vaccines. National Multiple Sclerosis Society. Available from: https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-mRNA-Vaccines. Accessed June 3, 2021.
   Google Scholar
• Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. Neurology. 2020;95(14):e1999–e2008. doi:10.1212/WNL.0000000000010380
   PubMed Web of Science ®Google Scholar
• Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord. 2020;45:102439. doi:10.1016/j.msard.2020.102439
   PubMed Web of Science ®Google Scholar
• Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis. Neurology. 2019;93(13):584–594. doi:10.1212/WNL.0000000000008157
   PubMed Web of Science ®Google Scholar